Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04195711 · ClinicalTrials.gov registry record
Comparative Validation of "Blinq" and "2WIN" Vision Screeners
A clinical trial, sponsored by Alaska Blind Child Discovery.
- Completed
- Registry status
- 100
- Enrollment target
NCT04195711: Completed study, sponsored by Alaska Blind Child Discovery.
NCT04195711 is a clinical trial that has completed, run by Alaska Blind Child Discovery. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04195711 has completed, sponsored by Alaska Blind Child Discovery.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
After 28 years of development, the binocular birefringence screener ("blinq," "Rebion") was commercially released. It need to be validated with AAPOS (American Association for Pediatric Ophthalmology and Strabismus) criteria in part because the next Uniform Standards document is pending. Adult and children pediatric and strabismus patients were screened with blinq and "2WIN" photoscreener with "CR" corneal reflex alignment test and then compared to confirmatory exam with age-appropriate determination of binocular status.
Primary Outcome
presence of refractive risk factor (anisometropia \>1.5 D, hyperopia\>3.5 D, astigmatism ≥1.5 D, myopia 3 D or more) and/or strabismus constant \>10 PD
Interventions
- DIAGNOSTIC_TEST objective pediatric vision screen, "blinq,"
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-11-18 |
| Est. Completion | 2019-11-26 |
What the finished NCT04195711 record still lists
NCT04195711 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which objective pediatric vision screen, "blinq," is the first listed.
NCT04195711 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04195711 about?
NCT04195711 is a clinical study titled "Comparative Validation of "Blinq" and "2WIN" Vision Screeners". After 28 years of development, the binocular birefringence screener ("blinq," "Rebion") was commercially released. It need to be validated with AAPOS (American Association for Pediatric Ophthalmology and Strabismus) criteria in part because the next Uniform Standards document is pending. Adult and ...
What is the current status of trial NCT04195711?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2019-11-18. Estimated completion is 2019-11-26.
What interventions are being tested in trial NCT04195711?
The interventions under investigation include: objective pediatric vision screen, "blinq," (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04195711?
This trial is sponsored by Alaska Blind Child Discovery, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI